Efficacy and safety analyses of bevacizumab in neoadjuvant chemotherapy for ovarian cancer: a systematic review and meta-analysis.

Wang Y, Wang Y, Wang L, Yuan H, Yu Y, Liu D

Open source

DOI
10.3389/fphar.2025.1566604
Published
2025
Container
Frontiers in pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2025.1566604,
  title = {Efficacy and safety analyses of bevacizumab in neoadjuvant chemotherapy for ovarian cancer: a systematic review and meta-analysis.},
  author = {Wang Y and Wang Y and Wang L and Yuan H and Yu Y and Liu D},
  year = {2025},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2025.1566604},
  url = {https://doi.org/10.3389/fphar.2025.1566604}
}

RIS

TY  - JOUR
TI  - Efficacy and safety analyses of bevacizumab in neoadjuvant chemotherapy for ovarian cancer: a systematic review and meta-analysis.
AU  - Wang Y
AU  - Wang Y
AU  - Wang L
AU  - Yuan H
AU  - Yu Y
AU  - Liu D
PY  - 2025
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2025.1566604
UR  - https://doi.org/10.3389/fphar.2025.1566604
ER  - 

APA

Y, W., Y, W., L, W., H, Y., Y, Y., & D, L. (2025). Efficacy and safety analyses of bevacizumab in neoadjuvant chemotherapy for ovarian cancer: a systematic review and meta-analysis.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2025.1566604

Source records